Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in pat… Read more
Tscan Therapeutics Inc (TCRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.225x
Based on the latest financial reports, Tscan Therapeutics Inc (TCRX) has a cash flow conversion efficiency ratio of -0.225x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.46 Million) by net assets ($144.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tscan Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tscan Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tscan Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tscan Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E3 LITHIUM LTD
F:OW3
|
-0.029x |
|
GrandTech C.G. Systems
TWO:6123
|
-0.014x |
|
New Ulm Telecom Inc
OTCQB:NUVR
|
0.059x |
|
Alarum Technologies Ltd.
NASDAQ:ALAR
|
0.096x |
|
Tureks Turizm Tasimacilik AS
IS:TUREX
|
0.424x |
|
Tradetool Auto Co Ltd
TWO:3685
|
-0.003x |
|
Serviceware SE
F:SJJ
|
N/A |
|
Kaset Thai International Sugar Corporation Public Company Limited
BK:KTIS
|
0.212x |
Annual Cash Flow Conversion Efficiency for Tscan Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tscan Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $240.97 Million | $-110.82 Million | -0.460x | -13.08% |
| 2023-12-31 | $150.87 Million | $-61.36 Million | -0.407x | +39.19% |
| 2022-12-31 | $99.43 Million | $-66.50 Million | -0.669x | -120.91% |
| 2021-12-31 | $160.78 Million | $-48.68 Million | -0.303x | -525.26% |
| 2020-12-31 | $-42.46 Million | $-3.02 Million | 0.071x | +124.19% |
| 2019-12-31 | $42.54 Million | $-12.52 Million | -0.294x | -- |